Kestra Medical (KMTS) CFO plans and tax sales total 6,995 shares

Rhea-AI Filing Summary

Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported selling 6,995 common shares on August 4, 2026. A sale of 3,080 shares at a weighted average $24.057 was a nondiscretionary sell-to-cover for RSU tax withholding, and a separate 3,915-share sale at $25.1696 occurred under a Rule 10b5-1 trading plan adopted November 6, 2025.

Insider Trade Summary 10b5-1

Net Seller: 6,995 shares

Net Sell 2 txns

Insider Mahboob Vaseem

Role Chief Financial Officer

Sold 6,995 shs ($173K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F2	3,080	$24.057	$74K
Sale	Common Shares F3, F4	3,915	$25.1696	$99K

Holdings After Transaction: Common Shares — 86,896 shares (Direct)

Footnotes (4)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9030 to $24.4200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025.
4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0000 to $25.3800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Shares sold for tax withholding: 3,080 shares Weighted avg price (tax sale): $24.057 per share Shares sold under 10b5-1 plan: 3,915 shares +3 more

6 metrics

Shares sold for tax withholding 3,080 shares Nondiscretionary sell-to-cover on August 4, 2026 for RSU tax obligations

Weighted avg price (tax sale) $24.057 per share First sale; prices ranged from $23.9030 to $24.4200

Shares sold under 10b5-1 plan 3,915 shares Sale on August 4, 2026 pursuant to a Rule 10b5-1 trading plan

Weighted avg price (10b5-1 sale) $25.1696 per share Second sale; prices ranged from $25.0000 to $25.3800

Total shares sold 6,995 shares Aggregate of reported sales on August 4, 2026

10b5-1 plan adoption date November 6, 2025 Adoption date for the CFO’s Rule 10b5-1 trading plan

Key Terms

sell to cover, restricted stock units, weighted average price, Rule 10b5-1 trading plan, +1 more

5 terms

sell to cover financial

"represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"in connection with the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 trading plan financial

"The reported transaction occurred pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

tax withholding obligations financial

"to satisfy tax withholding obligations in connection with the vesting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/06/2026 - 07:04 PM Accepted by SEC EDGAR 08/06/2026 - 07:04 PM Learn about SEC filing dates

FAQ

What insider transaction did Kestra Medical (KMTS) report in this Form 4?

Kestra Medical reported that CFO Mahboob Vaseem sold 6,995 common shares on August 4, 2026. The activity included a sell-to-cover transaction for RSU tax withholding and a separate sale executed under a pre-established Rule 10b5-1 trading plan.

How many Kestra Medical (KMTS) shares did CFO Mahboob Vaseem sell on August 4, 2026?

Mahboob Vaseem sold a total of 6,995 common shares on August 4, 2026. This consisted of 3,080 shares sold to cover RSU tax withholding and 3,915 shares sold in a separate transaction under a Rule 10b5-1 trading plan.

Were Mahboob Vaseem’s Kestra Medical (KMTS) share sales made under a Rule 10b5-1 plan?

One of the reported sales of 3,915 shares was made under a Rule 10b5-1 trading plan. The filing states this plan was adopted on November 6, 2025, indicating that transaction followed a pre-arranged trading schedule rather than discretionary timing.

Why were some of Mahboob Vaseem’s Kestra Medical (KMTS) shares sold?

A sale of 3,080 shares was a nondiscretionary sell-to-cover transaction. These shares were required to be sold to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units held by the CFO.

What prices were received in Mahboob Vaseem’s Kestra Medical (KMTS) share sales?

The sell-to-cover transaction had a weighted average price of $24.057 per share, with prices from $23.9030 to $24.4200. The 10b5-1 plan sale averaged $25.1696 per share, with individual prices ranging from $25.0000 to $25.3800.

Is there an indication of pre-planning for the Kestra Medical (KMTS) insider sale?

Yes. The filing notes that a 3,915-share sale occurred under a Rule 10b5-1 trading plan. It specifies this plan was adopted on November 6, 2025, and the document-level Rule 10b5-1 checkbox is marked as affirming use of such a plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahboob Vaseem

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/04/2026		S(1)		3,080	D	$24.057(2)	90,811	D
Common Shares	08/04/2026		S(3)		3,915	D	$25.1696(4)	86,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9030 to $24.4200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0000 to $25.3800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

	/s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)